SMA Newsroom

Novartis receives EMA CHMP positive opinion for Itvisma, gene therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA).

We are delighted to invite you to read the latest 20 Years of SMA Europe: From firefighting to future-building by Rare Revolution Magazine. 

We are delighted to invite you to read the latest Two decades of discovery: SMA research, from darkness to hope by Rare Revolution Magazine. 

We are delighted to invite you to read the latest "A seat, a voice, a vote: reimagining the role of SMA patient advocates in research and care” by Rare Revolution Magazine.